- Investing Ideas
- /
- Swiss Pharmaceuticals & Biotech High Growth Potential Companies
Swiss Pharmaceuticals & Biotech High Growth Potential Companies
UPDATED May 25, 2024
Companies with a Future performance score of at least 3, ordered by Future performance score.
14 companies
| Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | ||
|---|---|---|---|---|---|---|---|---|---|---|
NWRN | CHF9.52 | -10.2% | 118.3% | CHF177.4m | CHF14.48 | PS19.7x | E51.2% | n/a | ||
COPN | CHF71.50 | -1.9% | 42.7% | CHF1.1b | CHF93.31 | PE1008.4x | E30.4% | 2.8% | ||
BSLN | CHF43.90 | 0.6% | -6.9% | CHF529.9m | CHF70.58 | PE50.7x | E32.4% | 0% | ||
SDZ | CHF32.02 | 0.09% | n/a | CHF13.8b | CHF36.46 | PE195.4x | E29.5% | 1.4% | ||
GALD | CHF73.47 | -0.6% | n/a | CHF17.5b | CHF78.04 | PS4.6x | E42.9% | n/a | ||
LONN | CHF515.20 | -2.6% | -9.9% | CHF37.2b | CHF576.86 | PE56.8x | E20.7% | 0.8% | ||
TECN | CHF327.60 | -1.7% | -8.1% | CHF4.2b | CHF395.57 | PE31.8x | E9.2% | 0.9% | ||
NOVN | CHF91.74 | -1.7% | 3.2% | CHF187.2b | CHF98.82 | PE22.5x | E10.0% | 3.6% | ||
SKAN | CHF81.00 | 2.4% | 2.7% | CHF1.8b | CHF95.67 | PE69.2x | E18.7% | 0.4% | ||
ROG | CHF230.40 | -2.8% | -20.7% | CHF186.0b | CHF279.83 | PE16x | E8.7% | 4.2% | ||
BANB | CHF86.45 | -4.6% | -7.5% | CHF6.5b | CHF70.80 | PE57.9x | E15.4% | 0.9% | ||
ADXN | CHF0.069 | 1.8% | -45.1% | CHF8.9m | n/a | PS5.4x | E119.0% | n/a | ||
SFZN | CHF884.00 | -0.1% | 18.1% | CHF3.8b | CHF1,015.90 | PE33.6x | E14.7% | 0.4% | ||
PPGN | CHF31.95 | -3.8% | 33.2% | CHF1.1b | CHF24.55 | PS3.3x | E0.07% | 0% |
Page 1 of 1